"I'm an odd man out," says Rob Reinhart, who speaks out about his condition to encourage other men to be aware of potential ...

Rachel McGlynn wanted the choice to have kids to be hers — not dictated by the treatment for her condition. A decade into her ...

Scarlett Schneider was admitted to the hospital with dangerously low oxygen and an immune system that was attacking itself.

"I always knew something was wrong with me," says Nyobie Gordon-Ricks, a mom of two ...

Biogen’s lupus drug candidate litifilimab has improved outcomes in another phase 2 trial, adding to the momentum behind a program barreling toward pivotal data in two forms of t ...

Biogen announced positive results from the Phase 2 part of the AMETHYST Phase 2/3 study (part A) of investigational therapy, ...

CAR-T therapy is toting up more remissions in autoimmune disease, and generating a flood of experimentation and investment.

A retrospective study compared cardiovascular risks among patients with SLE who did and did not develop lupus nephritis and/or antiphospholipid antibody-positivity over time.

Lupus nephritis has a high burden of kidney and non-kidney damage accrual due to persistent disease activity, treatment-related toxicity, and age-related factors.

Italian researchers reporting in the journal Cancers found a 32% increase in the odds for cancer in the first year after a ...

Fate Therapeutics (NASDAQ:FATE) used a presentation at the Needham Healthcare Conference to outline its strategy for ...

Health Canada has granted a Notice of Compliance (NOC) for Saphnelo® (anifrolumab injection) for subcutaneous self-administration via a single-use autoinjector for adult patients with active, ...